These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 38110058)

  • 1. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
    Zhao Q; Liu H; Tang L; Wang F; Tolufashe G; Chang J; Guo JT
    Antiviral Res; 2024 Jan; 221():105782. PubMed ID: 38110058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What will it take to cure hepatitis B?
    Jeng WJ; Lok ASF
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    Wong GLH; Gane E; Lok ASF
    J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we cure hepatitis B virus with novel direct-acting antivirals?
    Martinez MG; Villeret F; Testoni B; Zoulim F
    Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a Functional Cure for Hepatitis B.
    Lok ASF
    Gut Liver; 2024 Jul; 18(4):593-601. PubMed ID: 38533651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
    J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon therapy of chronic hepatitis B.
    Brunetto MR; Bonino F
    Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigms in hepatitis B management: only diamonds are forever.
    Coffin CS; Lee SS
    Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG3
    Pang XQ; Li X; Zhu WH; Huang RK; Mo ZS; Huang ZX; Zhang Y; Xie DY; Gao ZL
    Antiviral Res; 2023 May; 213():105592. PubMed ID: 37004734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure.
    Chang ML; Liaw YF
    Drugs; 2023 Apr; 83(5):367-388. PubMed ID: 36906663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.